Search Results for "Bayer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Bayer. Results 11 to 20 of 124 total matches.
See also: aspirin

Acetaminophen, Nsaids and Alcohol

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996  (Issue 977)
mg q8h 650-mg caplets Aspirin Bayer (Sterling Health) 325-mg tablets or caplets plain or enteric ...
An advertising war between manufacturers of over-the-counter (OTC) analgesics has led some patients to ask their physicians about the safety of taking these products if they also drink alcohol.
Med Lett Drugs Ther. 1996 Jun 21;38(977):55-6 |  Show IntroductionHide Introduction

Topical Butenafine for Tinea Pedis

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997  (Issue 1004)
, solution Lotrimin (Schering-Plough) 3 6.17 4 Lotion, solution, powder, spray Mycelex (Bayer) 10.03 ...
Butenafine hydrochloride 1% cream (Mentax - Penederm), a benzylamine antifungal drug similar to the allylamines terbinafine (Lamisil) and naftifine (Naftin), is now available in the USA for topical treatment of tinea pedis, tinea corporis and tinea cruris.
Med Lett Drugs Ther. 1997 Jul 4;39(1004):63-4 |  Show IntroductionHide Introduction

PDE5 Inhibitors for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2012  (Issue 1383)
Vardenafil (Levitra – Bayer/GSK)3 30 min 4 hours 20 mg 2.5, 5, 10, 20 mg 21.99 1. May vary. 2. Cost ...
Sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some differences between them and new recommendations for their dosing (see Table 2) are worth noting.
Med Lett Drugs Ther. 2012 Feb 6;54(1383):10-1 |  Show IntroductionHide Introduction

Comparison Table: Some Systemic Fluoroquinolones (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
Cipro (Bayer) extended-release – generic Cipro XR Oral: 100, 250, 500, 750 mg tabs; 250 mg/5 mL ...
View the Comparison Table: Some Systemic Fluoroquinolones (online only)
Med Lett Drugs Ther. 2018 Mar 26;60(1543):e57-8 |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
in children $1.704 1.504 14.80 189.505,6 Salicylates Aspirin – generic Bayer (Bayer) 325 mg tabs; 500 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Trovafloxacin

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998  (Issue 1022)
USED FLUOROQUINOLONES Drug Daily dosage* Cost* Oral Ciprofloxacin − Cipro (Bayer) 500 to 750 mg bid ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Med Lett Drugs Ther. 1998 Mar 13;40(1022):30-1 |  Show IntroductionHide Introduction

Liletta - A Third Levonorgestrel-Releasing IUD

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
; ovarian cysts Mirena (Bayer) 5 years 0.2% Decreased menstrual bleed- Irregular bleeding in first 3-6 ...
The FDA has approved Liletta, an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):99-100 |  Show IntroductionHide Introduction

Cerivastatin for Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 1998  (Issue 1018)
FOR ONLINE USERS CERIVASTATIN FOR HYPERCHOLESTEROLEMIA Cerivastatin (Baycol − Bayer), a new HMG-CoA ...
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.
Med Lett Drugs Ther. 1998 Jan 16;40(1018):13-4 |  Show IntroductionHide Introduction

Phexxi - A Nonhormonal Contraceptive Gel

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
IUDs Kyleena (Bayer) Liletta (Abbvie/Medicines 360) Mirena (Bayer) Skyla (Bayer) 0.2% 0.1% 0.1 ...
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):129-32 |  Show IntroductionHide Introduction

Darolutamide (Nubeqa) for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019  (Issue 1587)
with The FDA has approved darolutamide (Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment ...
The FDA has approved darolutamide (Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen receptor inhibitor to be approved for this indication; apalutamide (Erleada) and enzalutamide (Xtandi), which are also approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC), were approved earlier.
Med Lett Drugs Ther. 2019 Dec 16;61(1587):201-2 |  Show IntroductionHide Introduction